Literature DB >> 18032792

Therapy for polycystic kidney disease? It's water, stupid!

Jared J Grantham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18032792     DOI： 10.1681/ASN.2007101100

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  7 in total

1.  Urine volume and change in estimated GFR in a community-based cohort study.

Authors:  William F Clark; Jessica M Sontrop; Jennifer J Macnab; Rita S Suri; Louise Moist; Marina Salvadori; Amit X Garg
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 8.237

2.  Novel treatments of autosomal dominant polycystic kidney disease.

Authors:  Rex L Mahnensmith
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

Review 3.  Predictors of autosomal dominant polycystic kidney disease progression.

Authors:  Robert W Schrier; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Keith Friend; Berenice Gitomer; Sandro Rossetti
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

4.  Polycystic kidney disease: Progression of polycystic kidney disease--a lack of progress?

Authors:  Stephen McDonald; Gopala Rangan
Journal:  Nat Rev Nephrol       Date:  2014-08-05       Impact factor: 28.314

5.  Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease?

Authors:  Eiji Higashihara; Kikuo Nutahara; Mitsuhiro Tanbo; Hidehiko Hara; Isao Miyazaki; Kuninori Kobayashi; Toshiaki Nitatori
Journal:  Nephrol Dial Transplant       Date:  2014-04-15       Impact factor: 5.992

6.  Increased water intake reduces long-term renal and cardiovascular disease progression in experimental polycystic kidney disease.

Authors:  Priyanka S Sagar; Jennifer Zhang; Magda Luciuk; Carly Mannix; Annette T Y Wong; Gopala K Rangan
Journal:  PLoS One       Date:  2019-01-02       Impact factor: 3.240

7.  Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.

Authors:  Franz Schaefer; Djalila Mekahli; Francesco Emma; Rodney D Gilbert; Detlef Bockenhauer; Melissa A Cadnapaphornchai; Lily Shi; Ann Dandurand; Kimberly Sikes; Susan E Shoaf
Journal:  Eur J Pediatr       Date:  2019-05-03       Impact factor: 3.183
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.